| 초록 |
siRNA-based drug delivery system has received great attention because it is an emerging class of molecules with a high potential for fulfilling the promise of geneetic medicine in areas like myocardial infarction therapy. Due to the instability and low delivery efficiencyof siRNAs, adequate strategies and formulations for siRNA protection, cellular uptake and endosomal release still need to be developed. In this study, we attempted to increase siRNA delivery efficiency by using facial amphipathic deoxycholic acid(DA)-modified polyethyleneimine(PEI1.8-DA)-RAGE siRNA. The receptor for advanced glycation end products(RAGE) plays a key role in the activation of pro-inflammatory pathways leading to enhancement of myocardial injury. Therefore, myocardial infarction(MI) therapeutic molecules, (PEI1.8-DA)-RAGE siRNA, is expected to increase protective activities following MI. Here, we tested the effects of PEI1.8-DA-RAGE siRNA on the protection of ischemic injuries. |
